A research team has now achieved promising results. Using epitope-focused immunogens, they were able to induce broadly neutralizing antibodies (bnAbs) in laboratory models for the first time.

In conclusion, because of their improved antigenic and immunogenic profiles, glycan-masked eOD-GT8 60mer mutants may serve as improved priming immunogens to elicit VRC01-class bnAbs in humans.

The induction of bnAbs is widely considered to be a goal of HIV vaccination, and this is the first step in that process. The immunogens being tested in IAVI G002 were developed by scientific teams at ...